Drug intelligence / Profile preview

MVT-301

Development stage: Preclinical
Lead developer: Microvascular Therapeutics
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

MVT-301 is an investigational therapeutic program developed by Microvascular Therapeutics for the treatment of Alzheimer's disease. It utilizes proprietary lipid-based nanobubbles in combination with focused ultrasound to target and dissolve amyloid-beta plaques and tau aggregates in the brain. By leveraging the physical effects of ultrasound-stimulated nanobubbles, the therapy aims to non-invasively clear pathological protein aggregates and potentially facilitate localized drug delivery across the blood-brain barrier.

Targets

MAPT (Microtubule-associated protein tau)Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on MVT-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVT-301.

Explore the full profile